Promises and caveats of in silico biomarker discovery

por Pusztai, L, Leyland-Jones, B
Publicado 2008

Of (only) mice and men

por Leyland-Jones, B, Grieshaber, C K
Publicado 1999

EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality

por Milano, G, Spano, J-P, Leyland-Jones, B
Publicado 2008

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer

por Aapro, M, Jelkmann, W, Constantinescu, S N, Leyland-Jones, B
Publicado 2012

Of mice and men: the evolution of animal welfare guidelines for cancer research

por Dey, N, De, P, Smith, B R, Leyland-Jones, B
Publicado 2010

Comparative analysis of xanafide cytotoxicity in breast cancer cell lines

por Alami, N, Paterson, J, Belanger, S, Juste, S, Grieshaber, C K, Leyland-Jones, B
Publicado 2007

Variation in RNA expression and genomic DNA content acquired during cell culture

por Hiorns, L R, Bradshaw, T D, Skelton, L A, Yu, Q, Kelland, L R, Leyland-Jones, B
Publicado 2004

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling

por Nakanishi, T, Chumsri, S, Khakpour, N, Brodie, A H, Leyland-Jones, B, Hamburger, A W, Ross, D D, Burger, A M
Publicado 2010

Prostate cancer genes associated with TMPRSS2–ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts

por Barwick, B G, Abramovitz, M, Kodani, M, Moreno, C S, Nam, R, Tang, W, Bouzyk, M, Seth, A, Leyland-Jones, B
Publicado 2010

Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian canc...

por Jean-Claude, B. J., Mustafa, A., Cetateanu, N. D., Damian, Z., De Marte, J., Yen, R., Vasilescu, D., Chan, T. H., Leyland-Jones, B.
Publicado 1997

Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform

por Abramovitz, M, Barwick, B G, Willis, S, Young, B, Catzavelos, C, Li, Z, Kodani, M, Tang, W, Bouzyk, M, Moreno, C S, Leyland-Jones, B
Publicado 2011

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer

por Chung, J H, Pavlick, D, Hartmaier, R, Schrock, A B, Young, L, Forcier, B, Ye, P, Levin, M K, Goldberg, M, Burris, H, Gay, L M, Hoffman, A D, Stephens, P J, Frampton, G M, Lipson, D M, Nguyen, D M, Ganesan, S, Park, B H, Vahdat, L T, Leyland-Jones, B, Mughal, T I, Pusztai, L, O’Shaughnessy, J, Miller, V A, Ross, J S, Ali, S M
Publicado 2017

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

por Hartmaier, R J, Trabucco, S E, Priedigkeit, N, Chung, J H, Parachoniak, C A, Vanden Borre, P, Morley, S, Rosenzweig, M, Gay, L M, Goldberg, M E, Suh, J, Ali, S M, Ross, J, Leyland-Jones, B, Young, B, Williams, C, Park, B, Tsai, M, Haley, B, Peguero, J, Callahan, R D, Sachelarie, I, Cho, J, Atkinson, J M, Bahreini, A, Nagle, A M, Puhalla, S L, Watters, R J, Erdogan-Yildirim, Z, Cao, L, Oesterreich, S, Mathew, A, Lucas, P C, Davidson, N E, Brufsky, A M, Frampton, G M, Stephens, P J, Chmielecki, J, Lee, A V
Publicado 2018